中国医院用药评价与分析
中國醫院用藥評價與分析
중국의원용약평개여분석
Evaluation and Analysis of Drug-Use in Hospitals of China
2015年
11期
1433-1436
,共4页
高血压病%温胆汤%苯磺酸左旋氨氯地平%临床疗效
高血壓病%溫膽湯%苯磺痠左鏇氨氯地平%臨床療效
고혈압병%온담탕%분광산좌선안록지평%림상료효
Hypertension%Wendan decoction%Levamlodipine besylate%Clinical efficacy
目的：探讨温胆汤加味联合苯磺酸左旋氨氯地平治疗高血压病的效果及安全性。方法：选取2012年10月—2014年10月收治的原发性高血压病患者90例作为研究对象，采用随机数字表法分为对照组和观察组各45例，对照组患者予苯磺酸左旋氨氯地平治疗，观察组患者在对照组治疗的基础上予温胆汤加味治疗，观察2组患者血管内皮功能、血压改善情况及临床疗效。结果：治疗8周后，观察组患者治疗总有效率为93.33％（42／45），显著高于对照组的77.78％（35／45）；舒张压和收缩压均显著低于对照组，差异均有统计学意义（P＜0.05）。观察组患者血压达标率为93.33％（42／45），显著高于对照组的75.56％（34／45），舒张压下降幅度显著高于对照组，治疗成本明显低于对照组，差异均有统计学意义（ P＜0.05）。观察组患者NO为（7.13±1.42）μmol／L，显著高于对照组的（4.52±1.49）μmol／L，心率、血尿素氮为（68.72±8.37）次／min、（4.36±0.51） mmol／L，显著低于对照组的（76.28±10.19）次／min、（4.97±0.69） mmol／L，差异均有统计学意义（P＜0.05）。结论：温胆汤加味联合苯磺酸左旋氨氯地平治疗高血压病，可将血压控制在正常水平，减少对内皮血管的损伤，改善患者心、肾功能，且无明显不良反应，值得临床推广。
目的：探討溫膽湯加味聯閤苯磺痠左鏇氨氯地平治療高血壓病的效果及安全性。方法：選取2012年10月—2014年10月收治的原髮性高血壓病患者90例作為研究對象，採用隨機數字錶法分為對照組和觀察組各45例，對照組患者予苯磺痠左鏇氨氯地平治療，觀察組患者在對照組治療的基礎上予溫膽湯加味治療，觀察2組患者血管內皮功能、血壓改善情況及臨床療效。結果：治療8週後，觀察組患者治療總有效率為93.33％（42／45），顯著高于對照組的77.78％（35／45）；舒張壓和收縮壓均顯著低于對照組，差異均有統計學意義（P＜0.05）。觀察組患者血壓達標率為93.33％（42／45），顯著高于對照組的75.56％（34／45），舒張壓下降幅度顯著高于對照組，治療成本明顯低于對照組，差異均有統計學意義（ P＜0.05）。觀察組患者NO為（7.13±1.42）μmol／L，顯著高于對照組的（4.52±1.49）μmol／L，心率、血尿素氮為（68.72±8.37）次／min、（4.36±0.51） mmol／L，顯著低于對照組的（76.28±10.19）次／min、（4.97±0.69） mmol／L，差異均有統計學意義（P＜0.05）。結論：溫膽湯加味聯閤苯磺痠左鏇氨氯地平治療高血壓病，可將血壓控製在正常水平，減少對內皮血管的損傷，改善患者心、腎功能，且無明顯不良反應，值得臨床推廣。
목적：탐토온담탕가미연합분광산좌선안록지평치료고혈압병적효과급안전성。방법：선취2012년10월—2014년10월수치적원발성고혈압병환자90례작위연구대상，채용수궤수자표법분위대조조화관찰조각45례，대조조환자여분광산좌선안록지평치료，관찰조환자재대조조치료적기출상여온담탕가미치료，관찰2조환자혈관내피공능、혈압개선정황급림상료효。결과：치료8주후，관찰조환자치료총유효솔위93.33％（42／45），현저고우대조조적77.78％（35／45）；서장압화수축압균현저저우대조조，차이균유통계학의의（P＜0.05）。관찰조환자혈압체표솔위93.33％（42／45），현저고우대조조적75.56％（34／45），서장압하강폭도현저고우대조조，치료성본명현저우대조조，차이균유통계학의의（ P＜0.05）。관찰조환자NO위（7.13±1.42）μmol／L，현저고우대조조적（4.52±1.49）μmol／L，심솔、혈뇨소담위（68.72±8.37）차／min、（4.36±0.51） mmol／L，현저저우대조조적（76.28±10.19）차／min、（4.97±0.69） mmol／L，차이균유통계학의의（P＜0.05）。결론：온담탕가미연합분광산좌선안록지평치료고혈압병，가장혈압공제재정상수평，감소대내피혈관적손상，개선환자심、신공능，차무명현불량반응，치득림상추엄。
OBJECTIVE:To investigate the efficacy and safety of modified Wendan decoction combined with levamlodipine besylate in the treatment of hypertension .METHODS:90 patients with essential hypertensive treated in the hospital from Oct.2012 to Oct.2014 were selected as the research objects.According to the random number table method, the patients were divided into the observation group and the control group , with 45 cases in each group .The control group were treated with levamlodipine besylate , while the observation group were additionally treated with modified Wendan decoction, on the basis of the control group .The vascular endothelial function and the improvement of blood pressure and clinical efficacy in the two group were observed .RESULTS:8 weeks of treatment later , the total effective rate in the observation group [93.33%(42/45)] was significantly higher than that in the control group [77.78%(35/45)].The diastolic and systolic blood pressure of the observation group were significant lower than those of the control group ( P<0.05).The control rate of blood pressure of the observation group [93.33%(42/45)] was significantly higher than that of the control group [75.56%(34/45) ];The falling range of diastolic blood pressure of the observation group was significantly higher than that of the control group, but the treatment cost was significantly lower than that of the control group (P<0.05). In the observation group , NO (7.13 ±1.42)μmol/L was significantly lower than that in the control group , while heart rate (68.72 ±8.37) time/min and blood urea nitrogen (4.36 ±0.51) mmol/L were significantly lower than those in the control group [(76.28 ±10.19)time/min and(4.97 ±0.69) mmol/L] (P<0.05).CONCLUSIONS:Modified Wendan decoction combined with levamlodipine besylate in the treatment of hypertension can control the blood pressure to the normal level , reduce the damage of vascular endothelium and improve cardiac and renal function without any obvious adverse reactions .It is worthy of clinical promotion .
